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ReceivedThe mass action equation is the building block from which all models of drug–receptor interaction are built. In the simplest case, the equation predicts a
sigmoidal relationship between the amount of drug–receptor complex and the logarithm of the concentration of drug. The form of this function is also
the same as most dose–response relationships in pharmacology (such as enzyme inhibition and the protein binding of drugs) but the potency term in
dose–response relationships very often differs in meaning from the similar term in the simple mass action relationship. This is because (i) most
pharmacological systems are collections of mass action reactions in series and/or in parallel and (ii) the important assumptions in the mass action
reaction are violated in complex pharmacological systems. In some systems, the affinity of the receptor R for some ligand A is modified by interaction of
the receptor with the allosteric ligand B and concomitantly the affinity of the receptor for ligand B is modified to the same degree. When this occurs, the
observed affinity of the ligand A for the receptor will depend on both the concentration of the co-binding allosteric ligand and its nature. The
relationships between drug potency in pharmacological models and the equilibrium dissociation constants defined in single mass action reactions are
discussed. More detailed knowledge of efficacy has led to new models of drug action that depend on the relative probabilities of different states, and







The mass action equation is the building block from which
all models of drug–receptor interaction are built. The present
review considers the assumptions underlying the applica-
tion of the equation to complex pharmacological systems,
the consequences of violations of the underlying assump-
tions and ways of overcoming the problems that arise.The mass action equation
The mass action equation was given in the work of
Guldberg and Waage [1], as follows:
Aþ B ⇋A’þ B’ (1)
Guldberg and Waage introduced the idea that the
rates of reactions, both forward and backward, depen-
ded on the ‘active masses’ (i.e. the concentrations) of
reactants in the mixture (‘…the amount of substancein the sphere of action’ or, put another way, the concen-
tration in the medium) [2]. Thus, at equilibrium, the
product of the active masses on one side of the equa-
tion divided by the product of the active masses on
the other side of the equation is a constant, indepen-
dent of the amount of substances at the start of the re-
action. This model has been applied to pharmacology,
and it underpins all models of drug activity. Specifically,
it defines the relationship between the quantity of the
drug ([A]) and the amount of drug–target complex
([AR]) formed; this latter species is the initiator of phar-
macological activity in all physiological processes.
It is useful to demonstrate how the law of mass action is
used to determine [AR] from the amount of drug ([A]) and
receptor ([R]), where the receptor is the drug target (recep-
tor, ion channel, enzyme). If the drug A and the receptor R
react with a rate constant k1 (units = s
1M1), the rate of
association of the drug with the receptor is given by k1
[A] [R]. Similarly, the rate constant for dissociation of the
drug from the receptor is denoted as k2 (units s
1) and de-
fines a rate of dissociation of the drug from the receptor ofarmacol / 81:1 / 41–51 / 41
T. Kenakink2 [AR]. The receptor conservation equation when the
stoichiometry of binding is 1:1 (accounting for all species
of receptor) is given as [RT] = [R] + [AR], where [RT] is the
total number of receptors and [R] the concentration of
free receptors (not bound by ligand). At equilibrium,
the rate of association of drug to the receptor is equal
to the rate of dissociation:
k1 A½  R½  ¼ k2 AR½  (2)
Defining a ratio KA as k2/k1:
KA ¼ A½  RT½   AR½ ð ÞAR½  (3)
This reduces to the mass action equation as applied
to pharmacology:
AR½  ¼ A½  RT½ 
A½  þ KA½  (4)
Equation 4 is the equation of a rectangular hyperbola,
which defines a sigmoidal curve on a semi-logarithmic
scale (see Figure 1). Specifically, this equation describes
a relationship whereby the product of the reaction (in
the case of equation 4, the drug–target complex) is a ra-
tio of the product of one of the reactants (drug concen-
tration [A]) multiplied by the maximal output capability
of the system (given by [RT]) and the sum of the reac-
tant ([A]) and a potency factor (apparent dissociation
constant KA) which, in the simplest case, is a measure
of the amount of reactant needed to carry the processFigure 1
The mass action equation as applied to the binding of a drug A to re-
ceptor R, to form complex AR. The amount of AR complex plotted as
a logarithmic function of the concentration yields a characteristic
sigmoidal curve. The sensitivity of the system to A is given by the KA
term (apparent dissociation constant) and gives the location parameter
of the curve along the x axis. The maximal ordinate value is given by
[RT], the maximal amount of receptor in the system. This curve closely
resembles the dose–response relationships for many drugs
42 / 81:1 / Br J Clin Pharmacolto half-maximal completion (see Figure 1). In the case
of equation 4, the potency factor is the equilibrium dis-
sociation constant of the drug–target complex. In terms
of target binding, when [A] = KA, half of the target sites
are bound with drug. Sigmoidal semi-logarithmic bind-
ing relationships form a main working tool of pharmacol-
ogy, the potency term in the denominator being a major
parameter of drug characterization. Specifically, the po-
tency term KA locates the binding curve along the concen-
tration axis. While the mass action reaction yields a
relationship of the same general form, it is fortuitous that
the potency observed in a binding curve sensitivity term
is also the formal term defined by the law of mass action
(namely, KA); there are instances where this is not the case.
Complexity in pharmacological binding may be due to two
factors. The first is that pharmacological systems may be
complex mixtures of mass action reactions (vide infra) and
the second is that real pharmacological systems violate
some of the basic assumptions essential to the mass action
reaction. The application of the law of mass action to phar-
macology must be considered in light of the assumptions
made in the derivation of this law for chemical reactions.
In terms of the pharmacological application, the following
assumptions are made:
1. All receptors are equally accessible to ligands –
violation of this assumption leads to incomplete
assessment of ligand binding.
2. The binding is reversible – violation of this assumption
precludes calculation of valid KA values.
3. Receptors are either free or bound to ligand, and there is
no more than one affinity state, or states of partial bind-
ing (the ligand and receptormust exist in only two states,
bound or unbound) – violation of this assumption leads
to ambiguity in the assignment of potency values.
4. Binding does not alter the ligand or receptor – violation
of this assumption also leads to ambiguity in the assign-
ment of potency values (system-dependent potency).
When a ligand binds to a receptor and changes its con-
formation, this is an expression of pharmacological
efficacy.
It will be seen that some of these assumptions are vio-
lated in the application of the mass action equation to
complex pharmacological systems, and it is worth iden-
tifying these violations in order to understand the
meaning of the parameters obtained from applying
mass action to pharmacological models.Mass action processes in series and
parallel
The essential feature of the law of mass action as applied to
drug binding to a target (equation 4) is that the balance
between the amounts of product ([AR]) and the amounts
Mass action applied to pharmacologyof the reactants ([A] + [R]) is determined by a simple ratio of
the rates of two reactions (see Figure 2A). If another process
interferes with any of the amounts of these species, then the
balance is changed and becomes dependent on more than
just the simple rates k1 and k2 (violation of assumption 4).
Therefore, if another reaction removes the product of the
first reaction ([AR] is depleted by another process) or if the
level of the reactants is altered by another reaction, then
the amount of [AR] will cease to be solely determined by
k1 and k2; this can occur if the complete system involves
series or parallel mass action processes.
Some pharmacological systems ostensibly follow sim-
ple mass action kinetics but are in effect simple mass
action reactions connected in series; series mass action
reactions lead to more complex interpretation of
potency values beyond simple KA values as described
by equation 4. In a series mass action system, a second
mass action reaction removes the product of the first
reaction, and therefore the rate of the overall reaction
depends upon the two processes (see Figure 2B). For
example, if ligand binding promotes the binding of the
ligand-occupied receptor to another species such as a
G protein in the cell membrane (i.e. if the protein ‘isomer-
izes’ [3] to becomes another thermodynamic species,Figure 2
Pharmacological systems as combinations of the simple mass action re-
action scheme (A). (B) A series mass action system where the product of
the first reaction becomes the reactant for the second. (C) A system
where two series mass action reactions are aligned in parallel with each
other, with a thermodynamic link between them. In this case, a protein
(ion channel) can exist in an open and closed conformation and drug A
can interact with both of themwhich then has a different reactivity to G proteins), then
the overall observed affinity of that ligand can be depen-
dent upon these interactive processes – i.e. the observed
potency of the ligand will not be equal to the equilibrium
dissociation constant as defined in equation 4.
Defining KA as ka2/ka1 and KG as kg2/kg1, the sensitivity
factor for the complete reaction (R to ARG) is not given by
KA but rather by a term:
Kobs ¼ KA1þ G½ =KG (5)
It can be seen from equation 5 that for all nonzero
values of [G], Kobs < KA; that is, the effective affinity of
the ligand for the receptor system will be greater than
its affinity for the receptor when it cannot interact with
the secondary membrane component (in this case, the
G protein). This has been shown experimentally in many
systems. For example, the clinically used β-adrenoceptor
agonist for asthma, salbutamol (albuterol), shows a five-
fold loss of affinity when complexation of the receptor
with a G protein is cancelled by addition of GTPγS [4].
Other pharmacological systems comprise parallel mass
action reactions; under these circumstances, the inter-
pretation of ligand potency becomes a complex result
of the makeup of the receptor system, not just the bind-
ing of the ligand to the receptor protein. In parallel mass
action systems, the reactants as well as the products may
be depleted by a second mass action reaction (see
Figure 2C). In these more complex systems (i.e. ion
channels or two-state receptor systems), the rate of the
overall reaction is an amalgam of the micro-rate
constants of the individual mass action processes.
The alteration of equilibria between protein states by li-
gand binding can be illustrated by two states in equilibrium
with each other as Rclosed and Ropen, controlled by an
allosteric constant L, which is defined as the ratio Ropen/
Rclosed:Under these circumstances, the sensitivity factor for the
complete system does not depend solely on KA (where
KA = k2/k1) but rather on the differential activity of the li-
gand for both target species, defined as the term α. This is
the ratio of the affinity of A for Ropen vs. its affinity for Rclosed:
Kobs ¼ KA 1þ Lð Þ
1þ αL (7)
Violation of receptor immutability (assumption 4)
A key violation of the simple mass action scheme is that
the receptor does not change upon ligand binding. IfBr J Clin Pharmacol / 81:1 / 43
T. Kenakinthe drug protein target consists of a system of intercon-
vertible protein conformations (see below) then the
binding of drugs in that system will necessarily change
the mix of receptors available for drug binding. In series
and parallel mass action reactions where there is a
thermodynamic bridge between species (making them
interconvertible, such as through the constant L in
scheme 6), the differential affinity of the ligand A for
the two receptor states (defined as the term α, where
α≠1) will necessarily lead to a change in the system from
that present in the absence of the ligand, through the ra-
tio ρ∞/ρ0 (where ρ0 is the fraction of receptors in the Ropen
state in the absence of ligand, and ρ∞ is the fraction in the
presence of a saturating concentration of ligand) in the




¼ α 1þ Lð Þ
1þ αLð Þ (8)
A mixture of receptor conformations will re-
equilibrate according to Le Chatelier’s principle (if a
chemical system is displaced from equilibrium, changes
will act to minimize the deviation from equilibrium)
towards enrichment of the protein species for which
the ligand has the greater affinity. Therefore, if α >1,
the active state (Ropen) will be enriched and if α <1, then
the inactive state (Rclosed) will be enriched. This idea is the
basic mechanism of drug efficacy and currently is
thought to be how a ligand causes a change in a receptor
system to initiate an increase in an active receptor
species that then elicits a cellular response.
The seven transmembrane receptors (7TMRs) are major
drug targets in therapeutic pharmacology. Such receptors
reside on the membrane surface of cells and mediate
chemical signalling from the environment to the cytoplasm
of the cell. They are characterized by having seven trans-
membrane helices joined by extracellular and cytoplas-
mic protein loops; their main function is to bind
hormones, neurotransmitters and autacoids to form a
complex, which then has consequences on the functions
of cells. Teleologically speaking, the main function of
7TMRs is to change their shape (conformation) in
response to interactions with extracellular ligands and
intracellular signalling proteins. In pharmacological
systems, drug targets such as 7TMRs do not stay in static
conformations but rather exist in ensembles of different
conformations, and these conformations are inter-
changeable according to the available free energy of
the system [6–11].
With a greater number of possible conformations in
the ensemble comes a much greater increase in the like-
lihood that drug binding will change the nature of the
system. For example, the effect of a saturating concentra-
tion of ligand on the fraction of receptors not in any44 / 81:1 / Br J Clin Pharmacolchosen state (e.g. state i) in an ensemble of one to n






















From equation 9 it can be seen that only in the case
where α1 = α2 = α3 = ... = αi = 1 (the ligand has the same
affinity for all states) will the ratio of states not change
upon ligand binding. This suggests that binding is not a
passive process and that the binding of a ligand will
change the energy landscape of the receptor ensemble.
A corollary of this idea is the notion that the ability of a
ligand to change the receptor ensemble is a far more
prevalent drug property than thought previously, when
there were limited pharmacological assays available to
measure drug response.
Under these circumstances, drugs bind not to a sin-
gle protein species but rather to a collection of tertiary
conformationally different proteins (i.e. an ensemble).
Probability partition functions show that ligand binding
is not a passive process but rather that it can actively
modify these ensembles [10–12]. Although there may
be numerous parallel mass action processes, and al-
though drug binding itself may change the nature of
the binding species (series mass action processes), the
overall effect of ligand binding in such a system can still
resemble a simple single mass action process and yield
a curve such as that shown in Figure 1 – i.e. the
dose–response relationship can be modelled by a rect-
angular hyperbola that yields an apparently sigmoid
curve after log transformation. However, as with the
examples shown in Figure 2B and 2C, the meaning of
the sensitivity term differs from the simple KA parame-
ter shown in equation 4.
Specific pharmacological models
The mass action relationship forms the basis of all major
drug activity models in pharmacology. For example, it
describes the initial binding of substrates to enzymes
(Figure 3A) [13]. Various combinations of mass action
equations form other models of important pharmacologi-
cal systems. Seriesmass action processes describe the bind-
ing of 7TMRs to agonists and subsequently to G proteins;
the model for agonism in general – namely, the Black–Leff
operational model [14] – is described by series mass action
equations for the binding of agonist to receptor and the
receptor to signal coupling proteins in cells (Figure 3B).
Parallel mass action equations describe the control of ion
channel opening and also for the allosteric function of
7TMRs (Figure 3C). While all of these models describe a
sigmoidal function on a semi-logarithmic scale for drug
concentration much in the same way as the mass action
Mass action applied to pharmacologyequation (Figure 1), the meaning of the sensitivity term
varies according to the specific model. The ascription of
the sensitivity term from the curves generated by theseTable 1
Meaning of the sensitivity term for some common pharmacological models
Target Term Definition
A. Enzymes Km Km
k1þk2
k1
B. Ion channels EC50 EC50 ¼ KA 1þLð Þ1þαLð Þ
C. 7TMRs (GPCRS) Kobs Kobs ¼ KA1þ G½ =KGð Þ
D. 7TMRs EC50 EC50 ¼ KA1þ RT½ =KEð Þ
E. 7TMRs EC50 EC50 ¼ KA 1þ B½ =KBð Þ1þα B½ =KBð ÞþτA 1þαβ B½ =ð
A. Michaelis–Menten enzyme kinetics: k1 = rate of substrate-enzyme association, k1 rate of s
B. Ion channel opening: α is the differential affinity of the ligand for the open ion channel, L
dissociation constant of the ligand-reeptor complex. C. Seven transmembrane receptor (7TM
protein complex. D. 7TMR function: [RT] is the receptor density, KE is the equilibrium dissocia
GPCRS, G protein-coupled receptors. E. 7TMR allosteric function: τA is the efficacy of the ago
allosteric ligand on agonist efficacy, KB is the equilibrium dissociation constant of the alloste
Figure 3
Series and parallel mass action reactions specified as distinct pharma-
cological models. (A) Mass action binding of a substrate to an enzyme
begins the process of enzyme catalysis in the Michaelis–Menten model
[13] for enzyme function. Once the substrate is bound, the enzyme
catalyses the reaction to production of product through k2 (also
referred to as kcat). (B) Two common settings for series mass action
reactions are the agonist-mediated production of ternary complexes
for G protein-coupled receptors and agonism as described by the
Black–Leff operational model [14]. (C) Two common parallel mass
action reactions involve drug activation of ion channels and the alloste-
ric model for seven transmembrane receptors [27, 28]models to a simple mass action reaction constant is
obviously inappropriate (i.e. see Table 1).
The sensitivity term in the sigmoidal relationships de-
scribed by these models (i.e. the KA term in equation 4) is
usually an important parameter in pharmacology as it
equates to drug potency – i.e. how much drug must be
present in the target compartment to achieve a given drug
response. There are two major areas where drug potencies
are important therapeutic parameters: (1) the EC50 of an
agonist, defined as the concentration producing a half-
maximal response and (2) the KB of antagonists, defined
as the concentration of antagonist producing 50% occu-
pancy of receptors. It is worth comparing the relationship
of these parameters to mass action reactions.
EC50 values for agonist potency
Pharmacological agonism is the process whereby
agonists bind to receptors to cause them to change their
behaviour toward the host cell, the outcome being a
change in cellular function. Conceptually, this can be
thought of as the binding of a drug A to a receptor R to
form an AR complex, which then changes its nature to














is the ratio of active state r
R) G protein binding; KG
tion constant of the ligand
nist, α the effect of the al
ric modulator–receptor coThe processes controlled by γ and ϕ (the conforma-
tional state of the 7TMR is not confined to AR) will modify
the observed affinity of the system for A and will be quite
different from the KA parameter defined by equation 4 [3].
If receptor R converts to R* upon binding of ligand A,
the observed affinity of the ligand for the system is not
defined by KA (equation 4) but rather an affinity thatrmacological significance
sitivity of enzyme to substrate
centration – i.e. concentration
ubstrate causing enzyme rate to
ain 50% of the maximum reaction velocity (Vmax)
ncentration of ligand producing the opening
alf of the channels
ncentration of binding ligand that causes
f-maximal production of ternary complex
ween ligand, receptor and G protein
ncentration of agonist producing 50% maximal response
ncentration of agonist producing 50% maximal response
he presence of an allosteric modulator
ion, k2 = rate of product formation once substrate bound.
eceptors and inactive state receptors, KA the equilibrium
is the equilibrium dissociation constant of the receptor–G
–receptor complex and the response elements of the cell.
losteric ligand [B] on agonist affinity, β is the effect of the
mplex.
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Figure 4
The sinistral displacement of functional activity curves for agonists
from the initial binding curve. The property of efficacy causes the con-
centration of agonist producing 50%maximal response (EC50) to be of a
lower magnitude than the binding constant KA. In the Black–Leff oper-
ational model, it is assumed that the initial agonist–receptor complex
AR interacts with response elements in the cell (denoted as E) to pro-
duce a further complex that causes cellular response. The sensitivity
factor for this second reaction is denoted KE and represents numerous
saturable processes within the cell cytosol. Efficacy in this model is
given as τ, where τ = [RT]/KE, ([RT] is the total number of receptors
T. Kenakindepends on the rate of the transformation to the R* state.
Under these circumstances, the complete reaction is not
characterized by the simple KA term but rather by an
amalgam term describing the series mass action
processes [3]:
Kobs ¼ K1þ γϕ
(11)
By definition, the change of the receptor to an active
state is a reflection of the ligand’s efficacy and it is useful
to discuss the concept of the efficacy and EC50 of a full
agonist in terms of the standard model for agonism in
pharmacology – namely, the Black–Leff operational
model [14, 15]:
Response ¼ A½  τ Em
A½  1þ τð Þ þ KA (12)
where the efficacy, τ, is [RT]/KE, which is the total
number of receptors divided by the equilibrium dissoci-
ation constant (KE = γ/φ from equation 4) of the
agonist-bound receptor–response element E complex.
The Black–Leff model can be thought of as a series
mass action system, whereby the agonist-bound and
activated receptor unites with elements in the cell to
produce a cellular response:46 /In terms of this model, the primary measure of agonist




This produces the well-known efficacy-mediated dis-
placement of functional agonist dose–response curves
to the left of the binding curve (see Figure 4).
In addition to agonism being a series mass action sys-
tem, receptors are known to be pleiotropic with respect
to the response elements with which they can interact
within cells. Thus, drugs can have many different effica-
cies, a phenomenon referred to as ‘pluridimensional effi-
cacy’ [16]. For example, calcitonin receptors can interact
with at least three G proteins in the membrane (Gs, Gq
and Gi), thereby creating a more diverse series of mass
action reactions (see Figure 5). This pleiotropy with
respect to mass action reactions may be an important
aspect of the therapeutic value of drugs in the clinic.
For instance, β-blockers theoretically should be valuable
in the treatment of heart failure but, of the many
β-blockers run in clinical trials, only a handful have shown
statistically significant improvement. It has been pro-
posed that the multiple actions of carvedilol (i.e. causing81:1 / Br J Clin Pharmacolblockade of β2- and α1-adrenoceptors and endothelin re-
sponses, and having antiproliferative and antioxidant ef-
fects) determine its clinical efficacy [17].
In addition, the alteration of receptor conformation
with agonist binding (according to scheme 10) can pro-
duce even greater diversity of agonist signalling through
the imposition of signalling bias [18–20]. Specifically,
there is abundant evidence that some ligands stabilize
unique states within the ensemble of normal receptor
systems, to cause differential activation of the pleiotropic
response elements in cells and thereby produce unique
signalling patterns. For example, while the natural sub-
stance angiotensin II causes activation of Gq protein
and β-arrestin through activation of angiotensin recep-
tors, the analogue TRV120027 stabilizes a conformation
that only activates β-arrestin (see Figure 6). This property
may make TRV120027 better for the treatment of heart
failure [21, 22].
KB values for antagonist target coverage
The main characteristic parameter for antagonists of
receptors, enzymes, or ion channels is the KB – namely,
the apparent equilibrium dissociation constant of the
antagonist–receptor complex. It can be seen from
the mass action equation (equation 4) that when the
Figure 5
Receptors are often pleiotropically linked to numerous signalling sys-
tems in the cell, and the activation of each of these can generate a sep-
arate concentration–response curve for drug effect. The key to
observing these is the availability of separate assays for each of the re-
sponses. Panel A. Schematic showing the interacting species of ligand
(A), receptor® and various response coupling elements labeled E1 to
E5. Panel B. Simulated concentration-response curves for interaction
of the ligand-bound receptor with the various response element
Mass action applied to pharmacologyantagonist concentration is equal to KB, the receptor oc-
cupancy for the antagonist is 50% of the total receptor
population. This is a characteristic condition as it repre-
sents a twofold diminution of agonist stimulation to the
system and generally characterizes the threshold for re-
ceptor antagonism. A common experimental approach
to the measurement of antagonist potency values KB is
through biochemical radioligand binding, most notablyFigure 6
The stabilization of unique receptor states can lead to the selective activation o
The activation of angiotensin receptors by angiotensin II normally leads to
β-arrestin. The structural analogue TRV120027 stabilizes a conformation of th
Gq. This phenomenon is generally referred to as biased receptor signalling. Data
curves for angiotensin activation of two signaling pathways (G-protein and β-ar
activation of β-arrestin but no activation of G proteinfor the target class 7TMRs. Owing to the apparent sim-
plicity of binding experiments, equation 4 is often di-
rectly applied to experimental data, with the
expectation that the sensitivity term obtained is an accu-
rate measure of KA: in some cases this may be correct but
in many others it is not. It is worth examining why, even
in binding experiments, the KA term in equation 4 is
often not what is obtained in pharmacological binding
experiments.
The relationship defining the binding of a drug to a
biological target was first presented by A.V. Hill [23] and
adopted by pharmacologists 6 years later in another hy-
perbolic relationship made popular by the chemist Irving
Langmuir, referred to as the adsorption isotherm [24].
Langmuir had applied this equation to the adsorption
of gas molecules onto surfaces, describing the interac-
tions as an attraction of molecules to the surface (a pro-
cess he denoted as ‘condensation’) and diffusion away
from the surface (a process he described as ‘evapora-
tion’). As discussed by the originators, this equation is of-
ten inappropriately applied to complex processes. For
example, Hill described the equation only to determine
‘…whether an equation of this type can satisfy all the ob-
servations, [rather] than to base any direct physical
meaning on … KA’ [italics in original] [25]. Langmuir
was primarily interested in the adsorption of gases to
metal surfaces, a non-interactive surface that is quitef some of the pleiotropic signalling mechanisms linked to the receptor.
the activation of the Gq protein and interaction of the receptor with
e receptor that causes interaction of the receptor with β-arrestin, not
for TRV120027 are redrawn from [36]. Panel A: Concentration response
restin- see left panel). Panel B: Biased signaling for TRV120027 showing
Br J Clin Pharmacol / 81:1 / 47
T. Kenakindifferent from receptor protein. In his paper, in describing
the use of the equation, Langmuir stipulated that any het-
erogeneity in the surface (such as might be found for acti-
vated charcoal) could alter the interpretation of the
parameters obtained: ‘…but it is evident that [the] Equa-
tion, which appl[ies] to adsorption by plane surfaces,
could not apply to adsorption by charcoal.’ [24]. As noted
previously, the fact that receptors do not have a uniform
conformation, but rather exist in ensembles of various
conformations, makes the ‘binding surface’ for ligands
nonhomogeneous. Therefore, while a process of mass ac-
tion binding takes place for drug action, the drug may
encounter a mixture of receptor conformations, all with
varying affinities for the drug. The different conforma-
tions in the ensemble are interchangeable, and ligands
may selectively stabilize some conformations over
others. If this occurs, binding may change the relative
proportions of these conformations, previously
discussed as conformational selection [5]. In view of
the heterogeneity of receptor systems in conforma-
tional ensembles, quite unlike Langmuir’s inert surface,
the mass action equation will not describe a single
binding process. Probability partition functions with
virtual data have shown that affinity and efficacy (as
defined by the changing of receptor conformation)
are necessarily correlated [12].
7TMRs are allosteric proteins – i.e. they co-bind a li-
gand in the extracellular space domain and a signalling
protein in the cytosolic domain of the cell. These interac-
tions depend on each other, in that the affinity of both
the ligand and the signalling protein depend on the
binding of the other species. Thus, agonism is the pro-
cess whereby extracellular ligands such as hormones or
neurotransmitters stabilize conformations of the recep-
tor that facilitate binding and activation of cellular signal-
ling proteins. The transfer of energy from the ligand
domain to the signalling domain of the receptor consti-
tutes an ‘allosteric vector’ [26], which is bidirectional, in
that the binding of a signalling protein to a receptor will
concomitantly alter the affinity of the receptor for a
ligand in other regions of the protein.
The allosteric protein binding model can be
described as a system of parallel mass action binding
reactions depicting the allosteric binding of two
ligands, A and B, to a single receptor protein, R (see
Figure 2C) [27, 28]:48 / 81:1 / Br J Clin PharmacolIn these systems, the affinity of receptor R for ligand A
is modified by interaction of the receptor with the allo-
steric ligand B by the factor α, and concomitantly the af-
finity of the receptor for ligand B is modified to the same
degree (namely, α) to ensure conservation of energy by
the binding of ligand A. When this occurs, the observed
affinity of ligand A for the receptor will depend on both
the concentration of the co-binding allosteric ligand
and its nature by the expression:
Kobs ¼ KA 1þ B½ =KBð Þ
1þ α B½ =KBð Þ (16)
Several allosteric ligands produce effects on ligand
receptor affinity through interactions at extracellular
and intracellular sites. The striking effects of co-binding
species are demonstrated by differences in the X-ray
crystallographic structure of the β2adrenoceptor
bound and not bound to a nanobody simulating a G
protein [29, 30]. Experiments with ghrelin receptors in
lipid discs have shown changes in the conformations of
the receptors on addition of Gq to nanodiscs [31]. Thus,
addition of β-arrestin causes formation of different re-
ceptor conformations, as seen with exponential fluores-
cent lifetime decay analysis [31]. Similarly, changes in
the conformations of κ-opioid receptors with the binding
of Gα16 and/or Gαi2 G protein subunits have been shown,
using the substituted cysteine accessibility method, to
produce an 18-fold change in affinity for the ligand
salvinorin [32]. The effect of receptors forming different
membrane complexes with signalling proteins has been
labelled ‘receptor distribution’ [33] and underscores the
heterogeneity of the drug target species in functional
pharmacological experiments. Given these effects,
apparently simple radioligand binding experiments with
7TMRs produce apparent KA values that may have no
relationship to the true micro-affinities of the ligands
for the receptor in the physiological environment.
In general, the nature of 7TMRs is very different from
the binding surface defined by equation 4 (i.e. the
available binding sites on 7TMRs most often do not
satisfy either of the prerequisites of uniformity and
non-interaction) and it is these differences that require
re-evaluation of the simple mass action equation as it
applies to the description of drug action.
Beyond Guldberg and Waage
All of the models discussed thus far are so-called ‘linkage’
models, in that the various species of receptor protein
present are defined, and linkages between them made
to equate and conserve energy transfer. While this
seemed to suffice when there were simple readouts of
ligand efficacy, they showed their inadequacy as
technology progressed to the point where multiple
assays report the complex behaviour of 7TMRs (efficacy
is pluridimensional [16]). Linkage models cannot
Mass action applied to pharmacologyaccommodate the clear evidence that these efficacies are
linearly related. For example, previously it had been
assumed that receptor internalization followed receptor
activation because the only scale for internalization was
the elimination of response. When separate assays were
available to measure receptor internalization directly, it
was seen that many antagonists which did not produce
receptor activation caused an active receptor internaliza-
tion [34, 35]. This overall independence in efficacy
requires more flexible models of receptor function than
the existing linkage models. Molecular dynamic models
fill the gap through the description of protein ‘ensem-
bles’, where a collection of receptors with differing
tertiary conformations comprise the systems that inter-
act with cells and ligands [6–9]. If such systems were to
be frozen in time for any one instant, it would be seen
that a collection of slightly different receptor conforma-
tions, of similar free energy, co-exist; ligands selectively
stabilize those for which they have the highest affinity
and these are selected at the expense of others – i.e.
ligands produce a new receptor ensemble for interaction
with the cytosolic signalling machinery [10–12]. Figure 7
shows an ensemble view of receptor function. As recep-
tors do not change conformation at a uniform rate in
every region of the protein, there will be a collection of
different global conformations, corresponding to specific
cytosolic states capable of activating signalling proteins.
Under these circumstances, a Boltzmann distribution of
states will be the so-called ‘active’ state of the receptor.
Ligands will have a range of affinities for these various
states and will selectively stabilize the states for which
they have the highest affinity (at the expense of others).
Thus, upon ligand binding, the ensembles will take on a
ligand-specific nature (see Figure 7). Note that there is
no forced linearity between pharmacological efficacies –
i.e. G protein activation does not need to precedeFigure 7
Receptor conformational ensembles as Boltzmann distributions of tertiary stat
sponses such as activation of Gαs, Gαi protein, β-arrestin interaction and recepto
formations are stabilized through selective high affinity at the expense of
physiologically active conformation within the ensemble, this confers that effica
Gαs, Gαi and β-arrestin (but does not internalize receptors) while ligand 2 activareceptor internalization; this fits new experimental evi-
dence showing that efficacies can be independent [37].
In contrast to linkage models, probability models
do not specify the protein species present but rather
describe the possibility of a given protein state chang-
ing into another state. For example, a model proposed
by Onaran and Costa [10] and Oneran et al. [11] begins
with one receptor state (referred to as [Ro]) and
defines the affinity of a ligand [A] and a G protein
[G] for that state as:
Ako ¼ ARo½ = Ro½  A½  (17)
and
Gko ¼ GRo½ = Ro½  G½  (18)
The probability of the receptor being in that state is
denoted po, while the probability of the receptor forming
another conformation [R1] is defined as p1. The probabil-
ity ratio for forming state R1 (denoted p1) vs. Ro (proba-
bility p0) is given as j1, where j1 = p1/po; the value j
controls the energy of transition between the states.
The relative probability of forming state [R1] with ligand
binding is denoted Aj1 =
Ap1/
Apo and with G protein bind-
ing as Gj1 =
Gp1/
Gpo. This defines vectors describing frac-
tional stabilization of states binding either ligand
(defined Ab1 =
Aj1/ji) or G protein (
Gb1 =
Gj1/ji), where
the magnitude of b is unique for each receptor state.
Therefore, values of b constitute ligand affinity and effi-
cacy. With these probabilities and vectors, the following
operators are:
Ω ¼ 1þ Σji (19)es. Shown are natural ensembles that lead to various physiological re-
r internalization. As different ligands bind to the ensemble, certain con-
other conformations. If the stabilized conformation coincides with a
cy upon the ligand. Shown are two different ligands. Ligand 1 activates
tes β-arrestin and causes receptor internalization
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ΩG ¼ 1þΩ ΣGbipi (21)
ΩAG ¼ 1þΩ ΣAbiGbipi (22)
where i refers to the specific conformational state and
the superscripts A and G refer to the ligand and G
protein-associated forms, respectively. Under these cir-
cumstances, macroaffinity is given by:
Macroaffinity Kð Þ ¼ Ak0ΩA Ωð Þ1 (23)
where the interaction free energy between ligand and a
reference microstate of the receptor is related to k0 and
efficacy is given by:
Efficacy αð Þ ¼ ΩΩAGð Þ ΩAΩGð Þ1 (24)
This model has been used to simulate the effects of
ligand binding on receptor ensembles and shows that
ligand affinity is positively correlated with ligand efficacy
[12]. These functions also can be used to describe biased
signalling owing to the stabilization of different receptor
ensembles that go on to activate different signalling
cascades [37, 38].Conclusions
It can be seen that there are most often differences
between the potencies of agonists or antagonists
measured in pharmacological experiments and the
simple equilibrium dissociation constant of a drug–
receptor complex defined by mass action. This occurs
even with such apparently simple experiments such
as radioligand binding of ligands to 7TMRs, where
the apparent KA value is really an amalgam of values
describing the complex ensemble of receptors and
their allosteric co-binding partners. However, the mass
action reaction, defined many years ago, still forms the
basis of all models describing drug action in
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